{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:24:47Z","timestamp":1793960687939,"version":"4.8.0"},"reference-count":0,"publisher":"HCA Healthcare","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HCA Healthcare Journal of Medicine"],"abstract":"<jats:p>Introduction \nPsoriasis is a chronic, multifactorial, inflammatory skin disease with several subtypes, including pustular psoriasis. Pustular psoriasis is characterized by pustules forming lakes of pus on the skin. Pro-inflammatory pathways, such as the interleukin (IL)-17\/IL-23 axis, have been shown to play a significant role in the pathogenesis of psoriasis. Biologic therapies directed towards these pro-inflammatory pathways have effectively treated plaque psoriasis, but fewer treatments have shown similar efficacy for pustular psoriasis.\nCase Presentation \nWe present a 45-year-old Black female who presented to the dermatology clinic with generalized pustular psoriasis affecting approximately 70% of her body surface area. She also noted joint stiffness and pain that was worse after inactivity. Her disease did not respond to previous treatment, which was using adalimumab for 6 months. She also had no response to a 3-month course of apremilast. Two weeks after receiving her first dose of risankizumab, she had complete clearance of her pustular psoriasis, affecting 0% of her body surface area. She also noted significant improvement in her joint pain.\nConclusions \nThere is little data regarding the efficacy of IL-23 inhibitors in treating generalized pustular psoriasis. To date, our case is the only reported instance in the literature showing rapid clearance of pustular psoriasis after 1 injection of risankizumab. This case illustrates that IL-23 inhibitors play an essential role in the rapid clearance of pustular psoriasis.<\/jats:p>","DOI":"10.36518\/2689-0216.1480","type":"journal-article","created":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T05:31:13Z","timestamp":1683955873000},"source":"Crossref","is-referenced-by-count":4,"title":["Complete Clearance of Pustular Psoriasis After A Single Dose of Risankizumab"],"prefix":"10.36518","volume":"4","author":[{"given":"Ashleigh E","family":"Hermann","sequence":"first","affiliation":[{"name":"Medical City Fort Worth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E","family":"Weis","sequence":"additional","affiliation":[{"name":"Medical City Weatherford"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22435","published-online":{"date-parts":[[2023,4,28]]},"container-title":["HCA Healthcare Journal of Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:30:00Z","timestamp":1793957400000},"score":1,"resource":{"primary":{"URL":"https:\/\/scholarlycommons.hcahealthcare.com\/hcahealthcarejournal\/vol4\/iss2\/20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,28]]}},"URL":"https:\/\/doi.org\/10.36518\/2689-0216.1480","relation":{},"ISSN":["2689-0216"],"issn-type":[{"value":"2689-0216","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}